Cureus · 2025
Early Experience With Robotic-Assisted Radical Cystectomy: A Six-Case Series From a UK Centre.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McAdam Jonathan, McAdam Andrew, Elhag Hafs, Beekharry Ramprakash
Аннотация
BACKGROUND: Robotic-assisted radical cystectomy (RARC) is increasingly adopted as a minimally invasive alternative to open radical cystectomy for muscle-invasive and high-risk non-muscle-invasive bladder cancer. This study presents early outcomes from the first six robotic cystectomies performed at a UK tertiary centre.
METHODS: A retrospective review was performed of the first six patients who underwent RARC between May and July 2025. Data collected included patient demographics, operative details, complications (graded by Clavien-Dindo), pathology, and follow-up outcomes.
RESULTS: The median age was 65.5 years (range: 54-70), with four males and two females. The median body mass index (BMI) was 29.1. The median total operative time was 466.5 minutes (range: 429-511), with estimated blood loss ranging from 200 to 900 mL. No patients required intraoperative transfusion or conversion to open surgery. Two patients developed postoperative ileus and one experienced stoma retraction; all were managed conservatively. There was no 30- or 90-day mortality. Pathology demonstrated stages ranging from Ta to T2a, with negative surgical margins in five cases, and one result awaited at the time of reporting. At an early median follow-up period, all patients were alive without evidence of recurrence.
CONCLUSIONS: RARC was safely introduced at our centre, with perioperative outcomes comparable to early series internationally. Ongoing data collection and longer follow-up are required to assess oncological durability and functional outcomes.
METHODS: A retrospective review was performed of the first six patients who underwent RARC between May and July 2025. Data collected included patient demographics, operative details, complications (graded by Clavien-Dindo), pathology, and follow-up outcomes.
RESULTS: The median age was 65.5 years (range: 54-70), with four males and two females. The median body mass index (BMI) was 29.1. The median total operative time was 466.5 minutes (range: 429-511), with estimated blood loss ranging from 200 to 900 mL. No patients required intraoperative transfusion or conversion to open surgery. Two patients developed postoperative ileus and one experienced stoma retraction; all were managed conservatively. There was no 30- or 90-day mortality. Pathology demonstrated stages ranging from Ta to T2a, with negative surgical margins in five cases, and one result awaited at the time of reporting. At an early median follow-up period, all patients were alive without evidence of recurrence.
CONCLUSIONS: RARC was safely introduced at our centre, with perioperative outcomes comparable to early series internationally. Ongoing data collection and longer follow-up are required to assess oncological durability and functional outcomes.